Lantidra Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Lantidra market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to a rise in the number of children affected by type 1 diabetes, increased public health awareness, greater regulatory flexibility for cell therapies, a heightened focus on autoimmune disease solutions, and an increase in both public and private funding for biotechnology.

The projected growth during the forecast period can be attributed to the rising prevalence of type-1 diabetes, increasing rates of obesity, a growing demand for beta cell replacement therapies, the widespread adoption of Western lifestyles, and an increase in immune system-related conditions. Major trends expected during this period include technological advancements in biomanufacturing, improvements in immunosuppressive drugs, innovations in insulin delivery systems, novel cell therapy solutions, and the integration of AI and personalized medicine.

The increasing prevalence of type-1 diabetes is expected to drive the growth of the Lantidra market. Type-1 diabetes is a chronic condition in which the immune system attacks the insulin-producing cells in the pancreas, resulting in insufficient insulin production and the need for lifelong insulin therapy to regulate blood sugar. The rise in type-1 diabetes cases is linked to factors such as genetic predisposition, environmental triggers such as viral infections, immune system dysfunction, and improved diagnostic methods. Lantidra, a treatment that involves transplanting insulin-producing cells from a donated pancreas, helps restore natural insulin production in patients with type-1 diabetes. This treatment improves blood sugar control, reduces insulin dependence, and may decrease the risk of complications. For example, between March 2022 and March 2023, the percentage of individuals with type-1 diabetes in the UK receiving all eight recommended care processes increased by 22%, according to the Office for Health Improvement & Disparities. This indicates that the growing prevalence of type-1 diabetes is fueling the growth of the Lantidra market.

Rising healthcare spending is also playing a significant role in the growth of the Lantidra market. Healthcare spending covers the financial resources allocated to medical treatments, hospital services, pharmaceuticals, and healthcare infrastructure. Factors such as an aging population, the increasing prevalence of chronic diseases, medical advancements, and higher demand for healthcare services contribute to rising healthcare spending. Increased spending supports investment in advanced treatments such as Lantidra, which improves patient outcomes and can lead to long-term savings. The growth in healthcare expenditure also ensures that innovative therapies reach a wider range of patients. For example, total health spending in Canada is expected to reach $344 billion in 2023, equating to $8,740 per person, reflecting a 2.8% increase from the previous year, according to the Canadian Institute for Health Information. This rise in healthcare spending is contributing to the growth of the Lantidra market.

A notable trend in the Lantidra market is the development of advanced therapies, such as allogeneic pancreatic islet cellular therapy, aimed at improving the management of type-1 diabetes by reducing the need for insulin injections. This therapy involves transplanting insulin-producing islet cells from a healthy donor into a recipient. The goal is to restore insulin production in individuals with type-1 diabetes who have lost this function due to damaged pancreatic cells. For example, in June 2023, CellTrans Inc., a U.S.-based biotechnology company, received FDA approval for Lantidra to provide insulin-producing beta cells, offering a potential solution for patients with severe hypoglycemia and insulin dependence. Administered via a single infusion into the liver’s portal vein, Lantidra may reduce or eliminate the need for insulin injections in some patients. However, patients may need to take immunosuppressive medications to maintain islet cell function, as outlined in the patient-directed labeling for Lantidra.

The key player in the lantidra market is CellTrans Inc.

North America was the largest region in the lantidra market in 2024. The regions covered in lantidra report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lantidra market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lantidra is a cell-based therapy designed to treat type 1 diabetes by using genetically modified donor pancreas cells to restore natural insulin production. This therapy helps reduce or eliminate the need for external insulin injections, offering improved blood sugar control. Its primary goal is to replace pancreatic function, providing a more sustainable solution and enhancing the quality of life for insulin-dependent patients.

Lantidra is available in injectable formulations, including subcutaneous injections, pre-filled syringes, and auto-injectors. The subcutaneous injectable formulation delivers medication under the skin for gradual absorption, allowing for controlled release and easy self-administration in patients with chronic conditions. Lantidra is used for various indications, such as delaying or preventing clinical type 1 diabetes, and treating newly diagnosed type 1 diabetes. It is suitable for a wide range of patient demographics, including pediatric, adult, and geriatric patients. The product is distributed through multiple channels, including direct sales, wholesalers, retail pharmacies, and online pharmacies. It is utilized by various end users, such as hospitals, specialty clinics, home healthcare providers, and research institutions.

The lantidra market research report is one of a series of new reports that provides lantidra market statistics, including the lantidra industry global market size, regional shares, competitors with the lantidra market share, detailed lantidra market segments, market trends, and opportunities, and any further data you may need to thrive in the lantidra industry. This lantidra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lantidra market consists of sales of genetically modified donor pancreas cells, cell transplantation, and immune suppression drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.